Details of Drug-Drug Interaction
| Drug General Information (ID: DDIQ1VBJS3) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Prednisolone | Drug Info | Trimethaphan | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antineoplastics | Antihypertensive Agents | |||||||
| Structure | |||||||||
| Mechanism of Prednisolone-Trimethaphan Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of antihypertensive agents Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Prednisolone | Trimethaphan | |||||||
| Mechanism |
Hypertensive effects Induction of sodium and fluid retention |
Antihypertensive agent Neuronal acetylcholine receptor Antagonist |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Neuronal acetylcholine receptor | Structure Sequence | |||||||
| Protein Family | Ligand-gated ion channel (TC 1.A.9) family | ||||||||
| Protein Function |
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||||||||||||||||
| 2 | Multum Information Services, Inc. Expert Review Panel. | ||||||||||||||||||

